<?xml version="1.0" encoding="UTF-8"?>
<p>The main non‐TNF antagonist biologics for IBD include the anti‐IL12/23 biologic ustekinumab and the anti‐integrin therapy, vedolizumab. Reassuringly, the risk of severe respiratory tract infections, severe infections in general or opportunistic infections does not appear to be increased in long‐term follow‐up studies of ustekinumab in both IBD and psoriasis.
 <xref rid="apt15779-bib-0080" ref-type="ref">
  <sup>80</sup>
 </xref>, 
 <xref rid="apt15779-bib-0081" ref-type="ref">
  <sup>81</sup>
 </xref>, 
 <xref rid="apt15779-bib-0082" ref-type="ref">
  <sup>82</sup>
 </xref> Similar data have also been reported for vedolizumab.
 <xref rid="apt15779-bib-0083" ref-type="ref">
  <sup>83</sup>
 </xref>, 
 <xref rid="apt15779-bib-0084" ref-type="ref">
  <sup>84</sup>
 </xref>, 
 <xref rid="apt15779-bib-0085" ref-type="ref">
  <sup>85</sup>
 </xref>, 
 <xref rid="apt15779-bib-0086" ref-type="ref">
  <sup>86</sup>
 </xref> There is a theoretical concern of an increased risk of respiratory infections, and hence COVID‐19, with vedolizumab treatment as vedolizumab binds the T‐cell integrin receptor α
 <sub>4</sub>β
 <sub>7,</sub> inhibiting its binding to MADCAM1 present on the small intestinal endothelium and vasculature. These receptors are also expressed in the T cells occupying the nares, although to a far lesser extent when compared to the intestine.
 <xref rid="apt15779-bib-0087" ref-type="ref">
  <sup>87</sup>
 </xref> Reassuringly, a recently conducted network meta‐analysis failed to demonstrate a significant difference in rates of nasopharyngitis between anti‐TNF agents and vedolizumab, and multiple studies on the safety of vedolizumab have demonstrated that there is no increased risk of respiratory, systemic or serious infections in patients on vedolizumab over placebo .
 <xref rid="apt15779-bib-0083" ref-type="ref">
  <sup>83</sup>
 </xref>, 
 <xref rid="apt15779-bib-0084" ref-type="ref">
  <sup>84</sup>
 </xref>, 
 <xref rid="apt15779-bib-0085" ref-type="ref">
  <sup>85</sup>
 </xref>, 
 <xref rid="apt15779-bib-0086" ref-type="ref">
  <sup>86</sup>
 </xref>
 <boxed-text position="anchor" content-type="box" id="apt15779-blkfxd-0004" orientation="portrait">
  <p>
   <bold>Biological therapies</bold>
   <list list-type="bullet" id="apt15779-list-0004">
    <list-item>
     <p>Biological therapies appear relatively safe.</p>
    </list-item>
    <list-item>
     <p>If commencing on a new patient, where appropriate consider subcutaneous dosing mechanism to reduce infusion centre burden/health facility contact.</p>
    </list-item>
    <list-item>
     <p>Elective switching from infliximab infusions to subcutaneous anti‐TNF formulations is not advised as this may increase the risk of relapse.
      <xref rid="apt15779-bib-0088" ref-type="ref">
       <sup>88</sup>
      </xref>
     </p>
    </list-item>
    <list-item>
     <p>If on combination therapy and patient is in deep remission and/or older, consider withholding/ceasing immunomodulator therapy to reduce infection risk. If possible utilise therapeutic drug monitoring to guide decision.</p>
    </list-item>
    <list-item>
     <p>If patient is in contact with someone who has COVID‐19, consider withholding anti‐TNF therapies for 2 weeks. Likely safe to continue other biologics.</p>
    </list-item>
    <list-item>
     <p>If patient tests positive for SARS‐CoV‐2 and/or develops COVID‐19, consider withholding biologics until patient clears infection.</p>
    </list-item>
   </list>
  </p>
 </boxed-text>
</p>
